ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer.

ABSTRACT:

Background/aim

Adjuvant chemotherapy for high-risk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on "high-risk" definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy.

Materials and methods

Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated.

Results

The overall recurr

SUBMITTER: Takaoka A 

PROVIDER: S-EPMC7880722 | biostudies-literature | 2021 Jan-Feb

REPOSITORIES: biostudies-literature